Evicenter
P&T meetings

Hovilpri (pritelivir)

Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults

Also known as AIC316
Last updated
239 sources

Product information and disease descriptionProduct descriptionProduct information

American hospital formulary service (AHFS), or other drug classification

3 evidence topics · 3 sources

AHFS classification

No evidence found.

ATC classification

No evidence found.

Pharmacologic class stated in the prescribing information

“HOVILPRI is a herpes simplex virus (HSV) helicase-primase inhibitor indicated in immunocompromised adults for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacyclovir, or famciclovir.” (opens the prescribing information at this quote)

“Pritelivir is a HSV helicase-primase inhibitor.” (opens the prescribing information at this quote)

KEGG DRUG classification
FieldQuoted record
Name“Pritelivir (USAN/INN)”
Efficacy“Antiviral, Helicase-primase inhibitor”
Comment“Treatment and suppression of herpes simplex virus (HSV) infection”
Target“Herpesvirus helicase-primase complex”
Brite hierarchy, level 1“Antimicrobials”
Brite hierarchy, level 2“Antivirals”
Brite hierarchy, level 3“Genome replication inhibitor”
Brite hierarchy, level 4“Other inhibitor”
NCI Drug Dictionary description

“A thiazolylamide and helicase-primase enzyme inhibitor that is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2).” (opens the source at this quote in a new tab)